Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
The WHO designation focuses on workforce training and technology transfer as manufacturing capacity expands across regions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The company launched to develop protein amplification technology intended for highly sensitive diagnostic testing. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Artis is bringing Syngoi Technologies to a US hub serving synthetic-DNA development and clinical manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Research reporting describes modified LNPs intended to improve delivery of mRNA cargo to lymph nodes. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies agreed to co-develop an approach to oral monoclonal-antibody delivery using exosomes derived from goat milk. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Eveo is designed to bring cell selection, activation, gene modification and final formulation into one closed workflow. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports an amino-acid formulation approach intended to improve LNP delivery for mRNA and CRISPR cargo. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports research linking internal lipid-nanoparticle structure with cargo delivery inside cells. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The acquisition brings InDevR's multiplexing capabilities into SSI Diagnostica's diagnostics and vaccine-development portfolio. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Bracco is extending its lipid-based microbubble technology into collaborations with cell-therapy developers and process teams. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Cellares will support automated manufacturing and release assays for gene-edited haematopoietic stem-cell therapies under development at Stanford Medicine. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Their collaboration covers RNA-interference medicines and includes upfront funding and potential development-linked payments. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
